Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Plasmodium heme detoxification system is a vital survival mechanism employed by malaria parasites during their intraerythrocytic developmental stage. As the parasite digests host hemoglobin to acquire essential amino acids, it releases large quantities of free heme (ferriprotoporphyrin IX), which is highly toxic to the parasite due to its ability to generate reactive oxygen species and disrupt cellular membranes (Jolt et al., 2008, Cell). To mitigate this toxicity, the parasite utilizes specialized proteins, most notably the Heme Detoxification Protein (HDP) and Histidine-Rich Proteins (HRP2 and HRP3), to catalyze the sequestration of free heme into chemically inert, insoluble crystals called hemozoin, or malaria pigment (Sullivan et al., 1996, Science). This detoxification process is the primary pharmacological target for several major classes of antimalarial drugs, particularly the quinolines. Drugs such as chloroquine and quinine bind to heme monomers or the growing faces of hemozoin crystals, preventing further polymerization and causing toxic heme to accumulate within the parasite's food vacuole. This accumulation leads to the rapid destruction of the parasite, making the system one of the most successful targets in the history of infectious disease therapy. However, the emergence of resistance through transporters like PfCRT and the deletion of biomarker proteins like HRP2 pose significant challenges to ongoing malaria control and elimination efforts (Nature Reviews Microbiology, 2011).
Inhibition of the biocrystallization of toxic free heme (ferriprotoporphyrin IX) into non-toxic, insoluble hemozoin crystals within the parasite's acidic food vacuole. This leads to the accumulation of free heme, which causes membrane damage and oxidative stress, ultimately resulting in parasite death (Egan, 2008, Future Microbiology; Coronado et al., 2014, Biochimica et Biophysica Acta).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium heme detoxification system (HDS).